

Citations

1. O'Sullivan GC, Kelly P, O'Halloran S et al. Probiotics: an emerging therapy. *Curr Pharm Des* 2005;11:3-10.
2. O'Sullivan GC. Probiotics. *Br J Surg* 2001;88:161-162.
- 2a. Bollinger RR, Barbas AS, Bush EL, et al. Biofilms in the large bowel suggest an apparent function of the human vermiform appendix. *J Theor Biol* (In press; available online Sep 7, 2007).
3. Allen SJ, Okoko B, Martinez E et al. Probiotics for treating infectious diarrhoea. *Cochrane Database Syst Rev* 2004;CD003048.
4. Floch MH, Montrose DC. Use of probiotics in humans: an analysis of the literature. *Gastroenterol Clin North Am* 2005;34:547-570, x.
5. Oggioni MR, Pozzi G, Valensin PE et al. Recurrent septicemia in an immunocompromised patient due to probiotic strains of *Bacillus subtilis*. *J Clin Microbiol* 1998;36:325-326.
6. Richard V, van der Auwera P, Snoeck R et al. Nosocomial bacteremia caused by *Bacillus* species. *Eur J Clin Microbiol Infect Dis* 1988;7:783-785.
7. Rautio M, Jousimies-Somer H, Kauma H et al. Liver abscess due to a *Lactobacillus rhamnosus* strain indistinguishable from L. *rhamnosus* strain GG. *Clin Infect Dis* 1999;28:1159-1160.
8. Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM. *Lactobacillus* endocarditis caused by a probiotic organism. *Clin Microbiol Infect* 1999;5:290-292.
9. Spinosa MR, Braccini T, Ricca E et al. On the fate of ingested *Bacillus* spores. *Res Microbiol* 2000;151:361-368.
10. Aura AM, Martin-Lopez P, O'Leary KA et al. In vitro metabolism of anthocyanins by human gut microflora. *Eur J Nutr* 2005;44:133-142.
11. Fleschhut J, Kratzer F, Reckemmer G, Kulling SE. Stability and biotransformation of various dietary anthocyanins in vitro. *Eur J Nutr* 2006;45:7-18.
12. Keppler K, Humpf HU. Metabolism of anthocyanins and their phenolic degradation products by the intestinal microflora. *Bioorg Med Chem* 2005;13:5195-5205.
13. Kaila M, Isolauri E, Saxelin M et al. Viable versus inactivated *Lactobacillus* strain GG in acute rotavirus diarrhoea. *Arch Dis Child* 1995;72:51-53.
14. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. *J Pediatr Gastroenterol Nutr* 2003;36:223-227.
15. Alander M, Satokari R, Korpela R et al. Persistence of colonization of human colonic mucosa by a probiotic strain, *Lactobacillus rhamnosus* GG, after oral consumption. *Appl Environ Microbiol* 1999;65:351-354.
16. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? *Am J Clin Nutr* 2006;83:1256-1264; quiz 1257.
17. Hammerman C, Bin-Nun A, Kaplan M. Safety of probiotics: comparison of two popular strains. *BMJ* 2006;333:1006-1008.
18. Salminen MK, Tynkynen S, Rautelin H et al. The efficacy and safety of probiotic *Lactobacillus rhamnosus* GG on prolonged, noninfectious diarrhea in HIV patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study. *HIV Clin Trials* 2004;5:183-191.
19. Cunningham-Rundles S, Ahrne S, Bengmark S et al. Probiotics and immune response. *Am J Gastroenterol* 2000;95:S22-S25.
20. Bin-Nun A, Bromiker R, Wilschanski M et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. *J Pediatr* 2005;147:192-196.
21. Lin HC, Su BH, Chen AC et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. *Pediatrics* 2005;115:1-4.
22. Saavedra JM. Clinical applications of probiotic agents. *Am J Clin Nutr* 2001;73:1147S-1151S.
23. Ishibashi N, Yamazaki S. Probiotics and safety. *Am J Clin Nutr* 2001;73:465S-470S.
24. Kaur IP, Chopra K, Saini A. Probiotics: potential pharmaceutical applications. *Eur J Pharm Sci* 2002;15:1-9.
25. Land MH, Rouster-Stevens K, Woods CR et al. *Lactobacillus* sepsis associated with probiotic therapy. *Pediatrics* 2005;115:178-181.
26. Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: a randomised controlled trial. *Arch Dis Child* 2005;90:892-897.
27. Ishida Y, Nakamura F, Kanzato H et al. Effect of milk fermented with *Lactobacillus acidophilus* strain L-92 on symptoms of Japanese cedar pollen allergy: a randomized placebo-controlled trial. *Biosci Biotechnol Biochem* 2005;69:1652-1660.
28. Peng GC, Hsu CH. The efficacy and safety of heat-killed *Lactobacillus paracasei* for treatment of perennial allergic rhinitis induced by house-dust mite. *Pediatr Allergy Immunol* 2005;16:433-438.
29. Viljanen M, Pohjavuori E, Haahtela T et al. Induction of inflammation as a possible mechanism of probiotic effect in atopic eczema-dermatitis syndrome. *J Allergy Clin Immunol* 2005;115:1254-1259.

Citations and Reference Literature: Probiotics

30. Viljanen M, Savilahti E, Haahtela T et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. *Allergy* 2005;60:494-500.
31. Viljanen M, Kuitunen M, Haahtela T et al. Probiotic effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants. *Pediatr Allergy Immunol* 2005;16:65-71.
32. Passeron T, Lacour JP, Fontas E, Ortonne JP. Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years. *Allergy* 2006;61:431-437.
33. MacGregor G, Smith AJ, Thakker B, Kinsella J. Yoghurt biotherapy: contraindicated in immunosuppressed patients? *Postgrad Med J* 2002;78:366-367.
34. Waligora-Dupriet AJ, Campeotto F, Nicolis I et al. Effect of oligofructose supplementation on gut microflora and well-being in young children attending a day care centre. *Int J Food Microbiol* 2006.
35. Bassler A. *Intestinal Toxemia (Autointoxication) Biologically Considered*. Philadelphia: FA Davis; 1930.
36. Sistek D, Kelly R, Wickens K et al. Is the effect of probiotics on atopic dermatitis confined to food sensitized children? *Clin Exp Allergy* 2006;36:629-633.
37. Levy SB. The 2000 Garrod lecture. Factors impacting on the problem of antibiotic resistance. *J Antimicrob Chemother* 2002;49:25-30.
38. Levy SB. The challenge of antibiotic resistance. *Sci Am* 1998;278:46-53.
39. Gottlieb SL, Newbern EC, Griffin PM et al. Multistate outbreak of listeriosis linked to turkey deli meat and subsequent changes in US regulatory policy. *Clin Infect Dis* 2006;42:29-36.
40. Grossman Z, Lorber M, Maayan S et al. Drug-resistant HIV infection among drug-naive patients in Israel. *Clin Infect Dis* 2005;40:294-302.
41. Schwab U, Allouche A, Doherty JF. Multidrug-resistant malaria from South Africa. *Clin Infect Dis* 2005;40:493.
42. Bartlett JG, Perl TM. The new *Clostridium difficile*—what does it mean? *N Engl J Med* 2005;353:2503-2505.
43. Bradshaw CS, Morton AN, Hocking J et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. *J Infect Dis* 2006;193:1478-1486.
44. Burgos M, Gonzalez LC, Paz EA et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. *Clin Infect Dis* 2005;40:968-975.
45. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents: a neglected modality for the treatment and prevention of selected intestinal and vaginal infections. *JAMA* 1996;275:870-876.
46. Schellenberg D, Bonington A, Champion CM et al. Treatment of *Clostridium difficile* diarrhoea with brewer's yeast. *Lancet* 1994;343:171-172.
47. Sheu BS, Cheng HC, Kao AW et al. Pretreatment with *Lactobacillus*- and *Bifidobacterium*-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual *Helicobacter pylori* infection after failed triple therapy. *Am J Clin Nutr* 2006;83:864-869.
48. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. *BMJ* 2002;324:1361.
49. Gionchetti P, Rizzello F, Venturi A, Campieri M. Probiotics in infective diarrhoea and inflammatory bowel diseases. *J Gastroenterol Hepatol* 2000;15:489-493.
50. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. *Pediatrics* 2005;115:5-9.
51. Surawicz CM, Elmer GW, Speelman P et al. Prevention of antibiotic-associated diarrhea by *Saccharomyces boulardii*: a prospective study. *Gastroenterology* 1989;96:981-988.
52. Bleichner G, Blehaut H, Mentec H, Moyse D. *Saccharomyces boulardii* prevents diarrhea in critically ill tube-fed patients: a multicenter, randomized, double-blind placebo-controlled trial. *Intensive Care Med* 1997;23:517-523.
53. Bassetti S, Frei R, Zimmerli W. Fungemia with *Saccharomyces cerevisiae* after treatment with *Saccharomyces boulardii*. *Am J Med* 1998;105:71-72.
54. Alvarez-Olmos MI, Oberhelman RA. Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. *Clin Infect Dis* 2001;32:1567-1576.
55. Can M, Besirbellioglu BA, Avci IY et al. Prophylactic *Saccharomyces boulardii* in the prevention of antibiotic-associated diarrhea: a prospective study. *Med Sci Monit* 2006;12:PI19-PI22.
56. Chapoy P. [Treatment of acute infantile diarrhea: controlled trial of *Saccharomyces boulardii*]. *Ann Pediatr (Paris)* 1985;32:561-563.
57. Arvola T, Laiho K, Torkkeli S et al. Prophylactic *Lactobacillus GG* reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. *Pediatrics* 1999;104:e64.

Citations and Reference Literature: Probiotics

58. Armuzzi A, Cremonini F, Bartolozzi F et al. The effect of oral administration of *Lactobacillus* GG on antibiotic-associated gastrointestinal side-effects during *Helicobacter pylori* eradication therapy. *Aliment Pharmacol Ther* 2001;15:163-169.
59. Armuzzi A, Cremonini F, Ojetto V et al. Effect of *Lactobacillus* GG supplementation on antibiotic-associated gastrointestinal side effects during *Helicobacter pylori* eradication therapy: a pilot study. *Digestion* 2001;63:1-7.
60. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of *Clostridium difficile*. *N Engl J Med* 2005;353:2433-2441.
61. Manzoni P, Mostert M, Leonessa ML et al. Oral supplementation with *Lactobacillus casei* subspecies *rhamnosus* prevents enteric colonization by *Candida* species in preterm neonates: a randomized study. *Clin Infect Dis* 2006;42:1735-1742.
62. Cummings JH, Kong SC. Probiotics, prebiotics and antibiotics in inflammatory bowel disease. *Novartis Found Symp* 2004;263:99-111; discussion 111-114.
63. Goldman CG, Barrado DA, Balcarce N et al. Effect of a probiotic food as an adjuvant to triple therapy for eradication of *Helicobacter pylori* infection in children. *Nutrition* 2006;22:984-988.
64. Pradhan A, Majumdar MK. Metabolism of some drugs by intestinal lactobacilli and their toxicological considerations. *Acta Pharmacol Toxicol (Copenh)* 1986;58:11-15.
65. Vos AP, Haarman M, Buco A et al. A specific prebiotic oligosaccharide mixture stimulates delayed-type hypersensitivity in a murine influenza vaccination model. *Int Immunopharmacol* 2006;6:1277-1286.
66. Moro G, Arslanoglu S, Stahl B et al. A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age. *Arch Dis Child* 2006;91:814-819.
67. Kukkonen K, Nieminen T, Poussa T et al. Effect of probiotics on vaccine antibody responses in infancy: a randomized placebo-controlled double-blind trial. *Pediatr Allergy Immunol* 2006;17:416-421.
68. Brunser O, Gotteland M, Cruchet S et al. Effect of a milk formula with prebiotics on the intestinal microbiota of infants after an antibiotic treatment. *Pediatr Res* 2006;59:451-456.
69. Abrams SA, Griffin IJ, Hawthorne KM et al. A combination of prebiotic short- and long-chain inulin-type fructans enhances calcium absorption and bone mineralization in young adolescents. *Am J Clin Nutr* 2005;82:471-476.
70. Hill LL, Foote JC, Erickson BD et al. *Echinacea purpurea* supplementation stimulates select groups of human gastrointestinal tract microbiota. *J Clin Pharm Ther* 2006;31:599-604.
71. Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. *J Pharmacol Sci* 2004;95:153-157.

Reference Literature

- [No authors listed.] *Lactobacillus sporogenes*. *Altern Med Rev* 2002;7(4):340-342. (Review)
- [No authors listed.] [Pouchitis, chronic inflammatory bowel diseases, irritable colon: to prevent with a bacteria-cocktail?] *MMW Fortschr Med* 2003;145(46):49. [German]
- [No authors listed.] Product review: probiotic supplements and foods (including *Lactobacillus acidophilus* and *Bifidobacterium*). Available at <http://www.consumerlab.com/results/probiotics.asp>. Accessed May 26, 2006.
- Agerbaek M, Gerdes LU, Richelsen B. Hypocholesterolaemic effect of a new fermented milk product in healthy middle-aged men. *Eur J Clin Nutr* 1995;49:346-352.
- Agerholm-Larsen L, Bell ML, Grunwald GK, et al. The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies. *Eur J Clin Nutr* 2000;54:856-860.
- Agerholm-Larsen L, Raben A, Haulrik N, et al. Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases. *Eur J Clin Nutr* 2000;54:288-297.
- Aiba Y, Suzuki N, Kabir AM, et al. Lactic acid-mediated suppression of *Helicobacter pylori* by the oral administration of *Lactobacillus salivarius* as a probiotic in a gnotobiotic murine model. *Am J Gastroenterol* 1998;93:2097-2101.
- Alsheikh A, Weizman Z. Safety of infant formula supplemented with two strains of probiotics in early infancy. Abstract 986. 2003 Pediatric Academic Societies' Annual Meeting. Seattle, May 3, 2003.
- Alvarez-Olmos MI. Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. *Clin Infect Dis* 2001;32(11):1567-1576.
- Anderson JW, Gilliland SE. Effect of fermented milk (yogurt) containing *Lactobacillus acidophilus* L1 on serum cholesterol in hypercholesterolemic humans. *J Am Coll Nutr* 1999;18:43-50.
- Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of *Lactobacillus* GG on antibiotic-associated gastrointestinal side-effects during *Helicobacter pylori* eradication therapy. *Aliment Pharmacol Ther* 2001;15:163-169.

Citations and Reference Literature: Probiotics

- Armuzzi A, Cremonini F, Ojetto V, et al. Effect of *Lactobacillus* GG supplementation on antibiotic-associated gastrointestinal side effects during *Helicobacter pylori* eradication therapy: a pilot study. *Digestion* 2001;63:1-7.
- Aronsson B, Barany P, Nord CE. *Clostridium difficile*-associated diarrhoea in uremic patients. *Eur J Clin Microbiol* 1987;6:352-356.
- Arunachalam K, Gill HS, Chandra RK. Enhancement of natural immune function by dietary consumption of *Bifidobacterium lactis* (HN019). *Eur J Clin Nutr* 2000;54:263-267.
- Arvola T, Laiho K, Torkkeli S, et al. Prophylactic *Lactobacillus* GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. *Pediatrics* 1999;104:e64.
- Asli G, Alsheikh A, Weizman A. Effect of formula supplemented with two strains of probiotics on infections in day care infants. Abstract 998. 2003 Pediatric Academic Societies' Annual Meeting. Seattle, May 3, 2003.
- Bajzer M, Seeley RJ. Physiology: obesity and gut flora. *Nature* 2006;444(7122):1009.doi:10.1038/4441009a.
- Balish E, Warner T. *Enterococcus faecalis* induces inflammatory bowel disease in interleukin-10 knockout mice. *Am J Pathol* 2002;160(6):2253-2257.
- Barbara G. Mucosal barrier defects in irritable bowel syndrome: who left the door open? *Am J Gastroenterol* 2006;101:1295-1298. (Editorial)
- Barefoot SF, Klaenhammer TR. Detection and activity of Lactacin B, a Bacteriocin produced by *Lactobacillus acidophilus*. *Appl Environ Microbiol* 1983;45:1808-1815.
- Bassetti S, Frei R, Zimmerli W. Fungemia with *Saccharomyces cerevisiae* after treatment with *Saccharomyces boulardii*. *Am J Med* 1998;105:71-72.
- Bassler A. Intestinal toxemia (autointoxication) biologically considered. Philadelphia: FA Davis Company; 1930.
- Bauer HW, Alloussi S, Egger G, et al. A long-term, multicenter, double-blind study of an *Escherichia coli* extract (OM-89) in female patients with recurrent urinary tract infections. *Eur Urol* 2005;47:542-548.
- Belkahl N, Maamouri N, Ouerghi H, et al. [Role of intestinal flora in inflammatory bowel disease and probiotics place in their management.] *Tunis Med* 2005;83(3):132-136. [French] (Review)
- Bengmark S. Colonic food: pre- and probiotics. *Am J Gastroenterol* 2000;95(1 Suppl):S5-S7. (Review)
- Bengmark S. Ecological control of the gastrointestinal tract: the role of probiotic flora. *Gut* 1998;42:2-7.
- Bengmark S. Ecnutrition and health maintenance: a new concept to prevent inflammation, ulceration and sepsis. *Clin Nutr* 1996;15:1-10.
- Beniwal RS, Arena VC, Thomas L, et al. A randomized trial of yogurt for prevention of antibiotic-associated diarrhea. *Dig Dis Sci* 2003;48:2077-2082.
- Bennet R, Nord CE. Development of the faecal anaerobic microflora after caesarean section and treatment with antibiotics in newborn infants. *Infection* 1987;15:332-336.
- Berman SH, Eichelsdoerfer P, Yim D. Daily ingestion of a nutritional probiotic supplement enhances innate immune function in healthy adults. *Nutr Res* 2006;26(9):454-459.
- Bernet M-F, Brassart D, Neeser J-R, et al. Adhesion of human bifidobacterial strains to cultured human epithelial cells and inhibition of enteropathogen-cell interactions. *Appl Environ Microbiol* 1993;59:4121-4128.
- Bernet M-F, Brassart D, Neeser JR, et al. *Lactobacillus acidophilus* LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. *Gut* 1994;35:483-489.
- Bertolami MC, Faludi AA, Batlouni M. Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia. *Eur J Clin Nutr* 1999;53:97-101.
- Bittner AC, Croffut RM, Stranahan MC, et al. Prescript-assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. *Clin Ther* 2005;27:755-761.
- Black FT, Andersen PL, Orskov J, et al. Prophylactic efficacy of lactobacilli on traveller's diarrhea. In: Steffen R, ed. *Travel medicine: Conference on International Travel Medicine 1*, Zurich, Switzerland. Berlin: Springer; 1989:333-335.
- Bleichner G, Blehaut H, Mentec H, et al. *Saccharomyces boulardii* prevents diarrhea in critically ill tube-fed patients: a multicenter, randomized, double-blind placebo-controlled trial. *Intensive Care Med* 1997;23:517-523.
- Borody TJ, Warren EF, Leis SM, et al. Bacteriotherapy using fecal flora: toying with human motions. *J Clin Gastroenterol* 2004;38(6):475-483. (Review)
- Borruel N, Casellas F, Guarner F. [Probiotics and inflammatory bowel disease.] *Gastroenterol Hepatol* 2002;25(9):552-559. [Spanish] (Review)
- Bos NA, Meeuwssen CG, Wostmann BS, et al. The influence of exogenous antigenic stimulation on the specificity repertoire of background immunoglobulin-secreting cells of different isotypes. *Cell Immunol* 1988;112:371-380.

Citations and Reference Literature: Probiotics

- Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. *Inflamm Bowel Dis* 2005;11:833-839.
- Boyle RJ, Robins-Browne RM, Tang MLK. Probiotic use in clinical practice: what are the risks? *Am J Clin Nutr* 2006;83(6):1255-1264. (Review)
- Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. *J Infect Dis* 2006;193(11):1478-1486.
- Brandtzaeg P. Molecular and cellular aspects of the secretory immunoglobulin system. *APMIS* 1995;103:1-19.
- Brigidi P, Swennen E, Vitali B, et al. PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption. *Int J Food Microbiol* 2003;81(3):203-209.
- Bruzzese E, Canani RB, De Marco G, et al. Microflora in inflammatory bowel diseases: a pediatric perspective. *J Clin Gastroenterol* 2004;38(6 Suppl):S91-S93. (Review)
- Buddington RK, Williams CH, Chen S-C, et al. Dietary supplement of Neosugar alters the fecal flora and decreases activities of some reductive enzymes in human subjects. *Am J Clin Nutr* 1996;63:709-716.
- Bukharin OV, Kuz'min MD, Ivanov IuB. [Correction of the microbiocenosis of the male urogenital tract in the course of hormonal therapy.] *Zh Mikrobiol Epidemiol Immunobiol* 2000;(4 Suppl):88-92. [Russian]
- Bullen CL, Willis AT. Resistance of the breast-fed infant to gastroenteritis. *BMJ* 1971;3:338-343.
- Burgio GR, Lanzavecchia A, Plebani A, et al. Ontogeny of secretory immunity: levels of secretory IgA and natural antibodies in saliva. *Pediatr Res* 1980;14:1111-1114.
- Buydens P, Debeuckelaere S. Efficacy of SF 68 in the treatment of acute diarrhea: a placebo-controlled trial. *Scand J Gastroenterol* 1996;31:887-891.
- Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? *Gastroenterology* 1999;116(5):1246-1249.
- Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. *Aliment Pharmacol Ther* 2000;14:1625-1629.
- Challa A, Ramkishan Rao D, Chawa CB, et al. Bifidobacterium longum and lactulose suppress azoxymethane-induced colonic aberrant crypt foci in rats. *Carcinogenesis* 1997;18:517-521.
- Chapoy P. Treatment of acute infantile diarrhea: controlled trial of Saccharomyces boulardii. *Ann Pediatr (Paris)* 1985;32:561-563. [French; English abstract]
- Chiang BL, Sheih YH, Wang LH, et al. Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses. *Eur J Clin Nutr* 2000;54:849-855.
- Clements ML, Levine MM, Black RE, et al. Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli. *Antimicrob Agents Chemother* 1981;20:104-108.
- Colombel JF, Cortot A, Neut C, et al. Yoghurt with Bifidobacterium longum reduces erythromycin-induced gastrointestinal effects. *Lancet* 1987;2:43.
- Cong Y, Konrad A, Iqbal N, et al. Probiotics and immune regulation of inflammatory bowel diseases. *Curr Drug Targets Inflamm Allergy* 2003;2(2):145-154. (Review)
- Cookson WO, Moffatt MF. Asthma: an epidemic in the absence of infection? *Science* 1997;275:41-42.
- Crabbé PA, Nash DR, Bazin H, et al. Immunohistochemical observations on lymphoid tissues from conventional and germ-free mice. *Lab Invest* 1970;22:448-457.
- Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. *Am J Gastroenterol* 2002;97:2744-2749.
- Cunningham-Rundles S, Ahrne S, Bengmark S, et al. Probiotics and immune response. *Am J Gastroenterol* 2000;95(1 Suppl):S22-25.
- Czerkinsky CC, Nilsson LÅ, Nygren H, et al. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody secreting cells. *J Immunol Methods* 1983;65:109-121.
- Dahlgren UI, Wold AE, Hanson LÅ, et al. Expression of a dietary protein in E. coli renders it strongly antigenic to gut lymphoid tissue. *Immunology* 1991;73:394-397.
- Dannaeus A. Age-related antibody response to food antigens. *Pediatr Allergy Immunol* 1993;4(Suppl 3):21-24.
- Darouiche RO, Thornby JJ, Cerra-Stewart C, et al. Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial. *Clin Infect Dis* 2005;41(10):1531-1534.
- David TJ. Infant feeding causes all cases of asthma, eczema, and hay fever: or does it? *Arch Dis Child* 1998;79:97-98.
- De Francesco V, Stoppino V, Sgarro C, et al. Lactobacillus acidophilus administration added to omeprazole/amoxicillin-based double therapy in Helicobacter pylori eradication. *Dig Liver Dis* 2000;32:746-747.

Citations and Reference Literature: Probiotics

- de Roos NM, Katan MB. Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. *Am J Clin Nutr* 2000;71(2):405-411.
- De Simone C, Ciardi A, Grassi A, et al. Effect of *Bifidobacterium bifidum* and *Lactobacillus acidophilus* on gut mucosa and peripheral blood B lymphocytes. *Immunopharmacol Immunotoxicol* 1992;14:331-340.
- De Simone C, Vesely R, Bianchi SB, et al. The role of probiotics in modulation of the immune system in man and in animals. *Int J Immunother* 1993;9:23-28.
- de Simone C. Impact of prebiotics and probiotics on enteric flora. *J Pediatr Gastroenterol Nutr* 2005;40(Suppl 1):S40. (Review)
- de Vrese M, Rautenberg P, Laue C, et al. Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination. *Eur J Nutr* 2005;44(7):406-413.
- de Vrese M, Winkler P, Rautenberg P, et al. Effect of *Lactobacillus gasseri* PA 16/8, *Bifidobacterium longum* SP 07/3, *B. bifidum* MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. *Clin Nutr* 2005;24:481-491.
- de Vrese M, Winkler P, Rautenberg P, et al. bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. *Vaccine* 2006;24(44-46):6670-6674.
- Deguchi Y, Morishita T, Mutai M. Comparative studies on synthesis of water-soluble vitamins among human species of bifidobacteria. *Agric Biol Chem* 1985;49:13-19.
- Demirer S, Aydinoglu S, Aslim B, et al. Effects of probiotics on radiation-induced intestinal injury in rats. *Nutrition* 2006;22(2):179-186.
- Desreumaux P, Colombel JF. [Intestinal flora and Crohn's disease.] *Ann Pharm Fr* 2003;61(4):276-281. [French] (Review)
- Desreumaux P, Colombel JF. [Intestinal microflora and chronic inflammatory bowel diseases.] *Gastroenterol Clin Biol* 2001;25(2 Pt 2):C89-93. [French]
- Desreumaux P. [New inflammatory bowel disease drugs targeting the inflammatory cascade.] *Gastroenterol Clin Biol* 2001;25(4 Suppl):B72-78. [French] (Review)
- Donnet-Hughes A, et al. Modulation of nonspecific mechanisms of defense by lactic acid bacteria: effective dose. *J Dairy Sci* 1999;82(5):863-869.
- Duman DG, Bor S, Ozutemiz O, et al. Efficacy and safety of *Saccharomyces boulardii* in prevention of antibiotic-associated diarrhoea due to *Helicobacter pylori* eradication. *Eur J Gastroenterol Hepatol* 2005;17:1357-1361.
- Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. *Am J Gastroenterol* 2006;101:1288-1294.
- Dunne C, Murphy L, Flynn S, et al. Probiotics: from myth to reality: demonstration of functionality in animal models of disease and in human clinical trials. *Antonie Van Leeuwenhoek* 1999;76(1-4):279-292. (Review)
- Dunne C. Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. *Inflamm Bowel Dis* 2001;7(2):136-145. (Review)
- Elhag KM, Senthilselvan A. A serogrouping scheme for the study of the epidemiology of *Bacteroides fragilis*. *J Med Microbiol* 1988;27:199-205.
- Elmer GW, Moyer KA, Vega R, et al. Evaluation of *Saccharomyces boulardii* for patients with HIV-related diarrhoea and in healthy volunteers receiving antifungals. *Microecol Ther* 1995;25:23-31.
- Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents: a neglected modality for the treatment and prevention of selected intestinal and vaginal infections. *JAMA* 1996;275:870-876. (Review)
- Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. *JAMA* 1996;275:870-876.
- Eskew PN Jr, Saywell RM Jr, Zollinger TW, et al. Trends in the frequency of cesarean delivery: a 21-year experience, 1970-1990. *J Reprod Med* 1994;39:809-817.
- Famularo G, Moretti S, Marcellini S, et al. Stimulation of immunity by probiotics. In: Fuller R, ed. *Probiotics: therapeutic and other beneficial effects*. London: Chapman and Hall; 1997:133-161.
- Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. *Gastroenterol Clin North Am* 2002;31(1):41-62. (Review)
- Faubion WA, Sandborn WJ. Probiotic therapy with *E. coli* for ulcerative colitis: take the good with the bad. *Gastroenterology* 2000;118:630-631.
- Favier C, Neut C, Mizon C, et al. Fecal b-D-galactosidase production and *Bifidobacteria* are decreased in Crohn's disease. *Dig Dis Sci* 1997;42(4):817-822.
- Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. *Inflamm Bowel Dis* 2004;10(3):286-299. (Review)
- Felley CP, Cortesey-Theulaz I, Rivero JL, et al. Favourable effect of an acidified milk (LC-1) on *Helicobacter pylori* gastritis in man. *Eur J Gastroenterol Hepatol* 2001;13:25-29.
- Folster-Holst R, Muller F, Schnopp N, et al. Prospective, randomized controlled trial on *Lactobacillus rhamnosus* in infants with moderate to severe atopic dermatitis. *Br J Dermatol* 2006;155:1256-1261.

Citations and Reference Literature: Probiotics

- Forrest BD. Identification of an intestinal immune response using peripheral blood lymphocytes. *Lancet* 1988;1:81-83.
- Free RH, Busscher HJ, Elving GJ, et al. Biofilm formation on voice prostheses: in vitro influence of probiotics. *Ann Otol Rhinol Laryngol* 2001;110(10):946-951.
- Friedlander A, Druker MM, Schachter A. Lactobacillus acidophilus and vitamin B complex in the treatment of vaginal infection. *Panminerva Med* 1986;28:51-53.
- Friedrich MJ. A bit of culture for children: probiotics may improve health and fight disease. *JAMA* 2000;284(11):1365-1366.
- Fuller R. A review: probiotics in man and animals. *J Appl Bacteriol* 1989;66:365-378.
- Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. *Gut* 2005;54:242-249.
- Gan BS, Kim J, Reid G, et al. Lactobacillus fermentum RC-14 inhibits Staphylococcus aureus infection of surgical implants in rats. *J Infect Dis* 2002;185(9):1369-1372.
- Garcia-Urkia N, Asensio AB, Zubillaga Azpiroz I, et al. [Beneficial effects of Bifidobacterium lactis in the prevention of bacterial translocation in experimental short bowel syndrome.] *Cir Pediatr* 2002;15(4):162-165. [Spanish]
- Gaskins HR. Immunological aspects of host/microbiota interactions at the intestinal epithelium. In: Mackie RI, White BA, Isaacson RE, eds. *Gastrointestinal microbiology: volume 2: gastrointestinal microbes and host interactions*. New York: International Thomson Publishing; 1997:537-587.
- Gataullin AG, Mikhailova NA, Blinkova LP, et al. [Properties of the isolated Bacillus subtilis strains and their influence on the intestinal microflora of experimental mice.] *Zh Mikrobiol Epidemiol Immunobiol* 2004;(2):91-94. [Russian]
- Gavrish TV. [Dysbioses of the oral cavity and intestines and immune reactivity in of adolescent bronchial asthma patients.] *Zh Mikrobiol Epidemiol Immunobiol* 2001;(6):74-77. [Russian]
- Ghosh S, van Heel D, Playford RJ. Probiotics in inflammatory bowel disease: is it all gut flora modulation? *Gut* 2004;53(5):620-622. (Review)
- Gibson GR, Beatty EH, Wang X, et al. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. *Gastroenterology* 1995;106:975-982.
- Gibson GR, Saavedra JM, Macfarlane S, et al. Gastrointestinal microbial disease and probiotics. In: Fuller R, ed. *Probiotics: therapeutic and other beneficial effects*. London: Chapman and Hall; 1997:10-39.
- Gibson GR, Wang X. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. *J Appl Bacteriol* 1994;77:412-420.
- Gibson GR. Dietary modulation of the human gut microflora using probiotics. *Br J Nutr* 1998;80(Suppl 2):S209-S212.
- Gill HS, Rutherford KJ, Cross ML, et al. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. *Am J Clin Nutr* 2001;74(6):833-839.
- Gill HS, Rutherford KJ, Cross ML. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. *J Clin Immunol* 2001;21(4):264-271.
- Gionchetti P, Lammers KM, Rizzello F, et al. VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics. *Gastroenterol Clin North Am* 2005;34(3):499-513, ix-x. (Review)
- Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. *Gastroenterology* 2003;124:1202-1209.
- Gionchetti P, Rizzello F, Venturi A, et al. Probiotics in infective diarrhoea and inflammatory bowel diseases. *J Gastroenterol Hepatol* 2000;15(5):489-493. (Review)
- Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. *Gastroenterology* 2000;119:305-309.
- Gismondo MR, Drago L, Lombardi A. Review of probiotics available to modify gastrointestinal flora. *Int J Antimicrob Agents* 1999;4:287-292.
- Goldman CG, Barrado DA, Balcarce N, et al. Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. *Nutrition* 2006;22(10):984-988.
- Golledge CL, Riley TV. "Natural" therapy for infectious diseases. *Med J Aust* 1996;164:94-95. (Review)
- Gorbach SL. Probiotics in the third millennium. *Dig Liver Dis* 2002;34(Suppl 2):S2-S7.
- Gorbach SL, Chang T, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. *Lancet* 1987;ii:1519.
- Goto E, He JX, Akao T, et al. Bioavailability of glycyrrhizin from Shaoyao-Gancao-Tang in laxative-treated rats. *J Pharm Pharmacol* 2005;57:1359-1363.
- Gotz V, Romankiewicz JA, Moss J, et al. Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation. *Am J Hosp Pharm* 1979;30:754-757.

Citations and Reference Literature: Probiotics

- Grönlund MM, Lehtonen OP, Eerola E, et al. Faecal microflora in healthy infants born by different methods of delivery: permanent changes in intestinal flora after caesarean delivery. *J Pediatr Gastroenterol Nutr* 1999;28:19-25.
- Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. *J Pediatr Gastroenterol Nutr* 2000;30:54-60.
- Guarner F. Microecology as a target for therapeutic intervention in inflammatory bowel disease. *Drugs* 2003;6(9):868-873. (Review)
- Guslandi M. Are probiotics effective for treating *Clostridium difficile* disease and antibiotic-associated diarrhea? *Nat Clin Pract Gastroenterol Hepatol* 2006;3(11):606-607.
- Guslandi M. Of germs in inflammatory bowel disease and of how to fight them. *J Gastroenterol Hepatol* 2003;18(1):115-116.
- Guslandi M. Probiotics for chronic intestinal disorders. *Am J Gastroenterol* 2003;98(3):520-521.
- Guslandi M. Targeting intestinal microflora in inflammatory bowel disease. *World J Gastroenterol* 2006;12(44):7225-7226.
- Halpern GM, Prindiville T, Blankenberg M, et al. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. *Am J Gastroenterol* 1996;91:1579-1585.
- Hamilton-Miller JM. The role of probiotics in the treatment and prevention of *Helicobacter pylori* infection. *Int J Antimicrob Agents* 2003;22:360-366.
- Hammerman C, Bin-Nun A, Kaplan M. Safety of probiotics: comparison of two popular strains. *BMJ* 2006;333:1006-1008.
- Hart AL, Stagg AJ, Kamm MA. Use of probiotics in the treatment of inflammatory bowel disease. *J Clin Gastroenterol* 2003;36(2):111-119. (Review)
- Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. *J Pharmacol Sci* 2004;95(2):153-157. (Review)
- Hasegawa H, Sung JH, Benno Y. Role of human intestinal *Prevotella oris* in hydrolyzing ginseng saponins. *Planta Med* 1997;63(5):436-440.
- Hasegawa H, Suzuki R, Wakabayashi C, et al. Synthesis of a biologically active fluorescent derivative of GM1, a main Ginseng saponin metabolite formed by intestinal bacteria. *Biol Pharm Bull* 1998;21:513-516.
- Hata D, Yoshida A, Ohkubo H, et al. Meningitis caused by bifidobacterium in an infant. *Pediatr Infect Dis* 1988;7:669-671.
- Hatakka K, Martio J, Korpela M, et al. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis-a pilot study. *Scand J Rheumatol* 2003;32(4):211-215.
- Hatakka K, Savilahti E, Ponka A, et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. *BMJ* 2001;322:1-5.
- Hawrelak JA, Myers SP. The causes of intestinal dysbiosis: a review. *Altern Med Rev* 2004;9(2):180-197. (Review)
- Hayakawa K, Mizutani J, Wada K, et al. Effects of soybean oligosaccharides on human faecal microflora. *Microb Ecology Health Dis* 1990;3:293-303.
- He JX, Akao T, Nishino T, et al. The influence of commonly prescribed synthetic drugs for peptic ulcer on the pharmacokinetic fate of glycyrrhizin from Shaoyao-Gancao-tang. *Biol Pharm Bull* 2001;24:1395-1399.
- He JX, Akao T, Tani T. Influence of co-administered antibiotics on the pharmacokinetic fate in rats of paeoniflorin and its active metabolite paeonimetabolin-I from Shaoyao-Gancao-tang. *J Pharm Pharmacol* 2003;55:313-321.
- He JX, Akao T, Tani T. Repetitive administration of Shaoyao-Gancao-tang to rats restores the bioavailability of glycyrrhizin reduced by antibiotic treatment. *J Pharm Pharmacol* 2003;55:1569-1575.
- He JX, Akao T, Tani T. Restorative effect of repetitive administration of Shaoyao-Gancao-tang on bioavailability of paeoniflorin reduced by antibacterial synthetic drugs treatment in rats. *Biol Pharm Bull* 2003;26:1585-1590.
- Heselmans M, Reid G, Akkermans LM, et al. Gut flora in health and disease: potential role of probiotics. *Curr Issues Intest Microbiol* 2005;6(1):1-7.
- Hidaka H, Eida T, Takizawa T, et al. Effects of fructooligosaccharides on intestinal flora and human health. *Bifidobacteria Microflora* 1986;5:37-50.
- Hill LL, Foote JC, Erickson BD, et al. Echinacea purpurea supplementation stimulates select groups of human gastrointestinal tract microbiota. *J Clin Pharm Ther* 2006;31(6):599.
- Hillman JD. Replacement therapy of dental caries. *Operative Dent J* 2001;(Fall Suppl):543.
- Hilton E, Isenberg HD, Alperstein P, et al. Ingestion of yogurt containing *Lactobacillus acidophilus* as prophylaxis for candidal vaginitis. *Ann Intern Med* 1992;116(5):353-357.
- Hilton E, Kolakowski P, Singer C, et al. Efficacy of *Lactobacillus GG* as a diarrheal preventive in travelers. *J Travel Med* 1997;4(1):41-43.
- Hilton E, Rindos P, Isenberg HD. *Lactobacillus GG* vaginal suppositories and vaginitis. *J Clin Microbiol* 1995;33:1433.

Citations and Reference Literature: Probiotics

- Hlivak P, Odraska J, Ferencik M, et al. One-year application of probiotic strain *Enterococcus faecium* M-74 decreases serum cholesterol levels. *Bratisl Lek Listy* 2005;106:67-72.
- Hogg C. T-helper polarization in atopic disease: how early does it occur? *Clin Exp Allergy* 1997;27:1237-1239.
- Holt PG. Immunoprophylaxis of atopy: light at the end of the tunnel? *Immunol Today* 1994;15:484-489.
- Hopkins MJ, Cummings JH, Macfarlane GT. Interspecies differences in maximum specific growth rates and cell yields of bifidobacteria cultured on oligosaccharides and other simple carbon sources. *J Appl Microbiol* 1998;85:381-386.
- Hove H, Norgaard H, Mortensen PB. Lactic acid bacteria and the human gastrointestinal tract. *Eur J Clin Nutr* 1999;53(5):339-350. (Review)
- Hughes VL. Microbiologic characteristics of *Lactobacillus* products used for colonization of the vagina. *Obstet Gynecol* 1990;75:244-248.
- Iizuka H, Takaishi H, Hibi T. [Probiotics for inflammatory bowel disease.] *Nippon Rinsho* 2005;63(5):776-780. [Japanese] (Review)
- Inoue K, Shirai T, Ochiai H, et al. Blood-pressure-lowering effect of a novel fermented milk containing gamma-aminobutyric acid (GABA) in mild hypertensives. *Eur J Clin Nutr* 2003;57:490-495.
- Ishida Y, Nakamura F, Kanzato H, et al. Clinical effects of *Lactobacillus acidophilus* strain L-92 on perennial allergic rhinitis: a double-blind, placebo-controlled study. *J Dairy Sci* 2005;88:527-533.
- Ishida Y, Nakamura F, Kanzato H, et al. Effect of milk fermented with *Lactobacillus acidophilus* strain L-92 on symptoms of Japanese cedar pollen allergy: a randomized placebo-controlled trial. *Biosci Biotechnol Biochem* 2005;69:1652-1660.
- Isolauri E, Arvola T, Sutas Y, et al. Probiotics in the management of atopic eczema. *Clin Exp Allergy* 2000;30:1604-1610.
- Isolauri E, Juntunen M, Rautanen T, et al. A human *Lactobacillus* strain (*Lactobacillus casei* sp strain GG) promotes recovery from acute diarrhea in children. *Pediatrics* 1991;88:90-97.
- Isolauri E, Sutas Y, Mäkinen-Kiljunen S, et al. Efficacy and safety of hydrolyzed cow milk and amino acid-derived formulas in infants with cow milk allergy. *J Pediatr* 1995;127:550-557.
- Isolauri E, Virtanen E, Jalonen T, et al. Local immune response measured in blood lymphocytes reflects the clinical reactivity of children with cow's milk allergy. *Pediatr Res* 1990;28:582-586.
- Ito M, Deguchi Y, Miyamori A, et al. Effects of administration of galactooligosaccharides on the human faecal microflora, stool weight and abdominal sensation. *Microb Ecology Health Dis* 1990;3:285-292.
- Jang T, Saviano DA. In vitro fermentation by human colonic bacteria is modified by *Lactobacillus acidophilus* supplementation. *J Nutr* 1997;127(8):1489-1495.
- Jauhiainen T, Vapaatalo H, Poussa T, et al. *Lactobacillus helveticus* fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. *Am J Hypertens* 2005;18:1600-1605.
- Jeavons HS. Prevention and treatment of vulvovaginal candidiasis using exogenous *Lactobacillus*. *J Obstet Gynecol Neonatal Nurs* 2003;32:287-296.
- Jenkins B, Holsten S, Bengmark S, et al. Probiotics: a practical review of their role in specific clinical scenarios. *Nutr Clin Pract* 2005;20(2):262-270. (Review)
- Johansson M-L, Molin G, Jeppsson B, et al. Administration of different *Lactobacillus* strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. *Appl Environ Microbiol* 1993;59:15-20.
- Jonkers D, Stockbrugger R. Probiotics and inflammatory bowel disease. *J R Soc Med* 2003;96(4):167-171. (Review)
- Kalliomaki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomized placebo controlled trial. *Lancet* 2001;357(9262):1076-1079.
- Kanamori Y, Hashizume K, Sugiyama M, et al. Combination therapy with *Bifidobacterium breve*, *Lactobacillus casei*, and galactooligosaccharides dramatically improved the intestinal function in a girl with short bowel syndrome: a novel synbiotics therapy for intestinal failure. *Dig Dis Sci* 2001;46(9):2010-2016.
- Kanauchi O, Matsumoto Y, Matsumura M, et al. The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease. *Curr Pharm Des* 2005;11(8):1047-1053. (Review)
- Kanauchi O, Mitsuyama K, Araki Y, et al. Modification of intestinal flora in the treatment of inflammatory bowel disease. *Curr Pharm Des* 2003;9(4):333-346. (Review)
- Kantele A. Immune response to prolonged intestinal exposure to antigen. *Scand J Immunol* 1991;33:225-229.
- Kantele AM, Takanen R, Arvilommi H. Immune response to acute diarrhea seen as circulating antibody-secreting cells. *J Infect Dis* 1988;158:1011-1016.
- Kantele JM, Kantele A, Arvilommi H. Circulating immunoglobulin-secreting cells are heterogeneous in their expression of maturation markers and homing receptors. *Clin Exp Immunol* 1996;104:525-530.

Citations and Reference Literature: Probiotics

- Karimi O, Pena AS, van Bodegraven AA, et al. Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study. *Drugs Today (Barc)* 2005;41:453-459.
- Karimi O, Pena AS. Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease: prospective randomized trials are necessary. *Rev Esp Enferm Dig* 2005;97(8):570-574. (Review)
- Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. *Aliment Pharmacol Ther* 2004;20:1133-1141.
- Kawase K. Effects of nutrients on the intestinal microflora of infants. *Jpn J Dairy Food Sci* 1982;31:A241-243.
- Kennedy RJ, Kirk SJ, Gardiner KR. Probiotics in IBD. *Gut* 2001;49(6):873.
- Kidd PM. Autism, an extreme challenge to integrative medicine: part 2: medical management. *Altern Med Rev* 2002;7(6):472-499. (Review)
- Kidd PM. Autism, an extreme challenge to integrative medicine: part 1: the knowledge base. *Altern Med Rev* 2002;7(4):292-316. (Review)
- Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. *Aliment Pharmacol Ther* 2003;17:895-904.
- Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. *Neurogastroenterol Motil* 2005;17:687-696.
- Kim HS, Park H, Cho IY, et al. Dietary supplementation of probiotic *Bacillus polyfermenticus*, Bispan strain, modulates natural killer cell and T cell subset populations and immunoglobulin G levels in human subjects. *J Med Food* 2006;9(3):321-327.
- Kim YG, Moon JT, et al. [The effects of probiotics on symptoms of irritable bowel syndrome.] *Korean J Gastroenterol* 2006;47(6):413-419.
- Kirchhelle VA, Fruhwein N, Toburen D. Treatment of persistent diarrhea with *Saccharomyces boulardii*: results of a prospective study. *Fortschr Med* 1996;114:136-140. [German; English abstract]
- Kirchhelle VA, Fruhwein N, Toburen D. Treatment of persistent diarrhea with *Saccharomyces boulardii*: results of a prospective study. *Fortschr Med* 1996;114:136-140. [German; English abstract]
- Kir'ianova VV, Gorbacheva KV. [Use of zinc sulfate and sodium thiosulfate electrophoresis in treating patients with intestinal dysbacteriosis.] *Vopr Kurortol Fizioter Lech Fiz Kult* 2002;(3):28-30. [Russian]
- Kirillov DA, Chainikova IN, Perunova NB, et al. [Effect of a polyoxydonium immunoregulator on the biological properties of microorganisms.] *Zh Mikrobiol Epidemiol Immunobiol* 2003;(4):74-78. [Russian]
- Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. *J Pediatr Gastroenterol Nutr* 2003;36:223-227.
- Kjeldsen J, Brynskov J, Madsen JR. [New therapies of chronic inflammatory bowel disease: anti-TNF antibodies and probiotics: the Danish Society of Gastroenterology.] *Ugeskr Laeger* 2001;163(12):1707. [Danish]
- Kleeman EG, Klaenhammet TR. Adherence of *Lactobacillus* species to human fetal intestinal cells. *J Dairy Sci* 1982;65:2063-2069.
- Kleessen B, Bunke H, Tovar K, et al. Influence of two infant formulas and human milk on the development of the faecal flora in newborn infants. *Acta Paediatr* 1995;84:1347-1356.
- Koebnick C, Wagner I, Leitzmann P, et al. Probiotic beverage containing *Lactobacillus casei* Shirota improves gastrointestinal symptoms in patients with chronic constipation. *Can J Gastroenterol* 2003;17:655-659.
- Kollaritsch H, Wiedermann G. Traveller's diarrhoea among Austrian tourists: epidemiology, clinical features and attempts at nonantibiotic drug prophylaxis. In: Pasini W, ed. *Proceedings of the second international conference on tourist health*. Rimini: World Health Organisation; 1990:74-82.
- Kollaritsch VH, Holst H, Grobara P, et al. Prevention of traveler's diarrhea with *Saccharomyces boulardii*: results of a placebo-controlled double-blind study. *Fortschr Med* 1993;111:152-156. [German]
- Kontiohari T, Sundqvist K, Nuutinen M, et al. Randomised trial of cranberry-lingonberry juice and *Lactobacillus GG* drink for the prevention of urinary tract infections in women. *BMJ* 2001;322:1571-1573.
- Koo OM, Rao AV. Long-term effect of bifidobacteria and Neosugar on precursor lesions of colonic cancer in CF1 mice. *Nutr Rev* 1991;51:137-146.
- Korzenik JR, Podolsky DK. Evolving knowledge and therapy of inflammatory bowel disease. *Nat Rev Drug Discov* 2006;5(3):197-209. (Review)
- Kotowska M, Albrecht P, Szajewska H, et al. *Saccharomyces boulardii* in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. *Aliment Pharmacol Ther* 2005;21:583-590.
- Kramer DR, Cebra JJ. Early appearance of "natural" mucosal IgA responses and germinal centers in suckling mice developing in the absence of maternal antibodies. *J Immunol* 1995;154:2051-2062.

Citations and Reference Literature: Probiotics

- Kukkonen K, Nieminen T, Poussa T, et al. Effect of probiotics on vaccine antibody responses in infancy: a randomized placebo-controlled double-blind trial. *Pediatr Allergy Immunol* 2006;17(6):416-421.
- Kukkonen K, Savilahti E, Haahtela T, et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. *J Allergy Clin Immunol* 2006;119(1):192-198. Published online Oct 27, 2006.
- Kurugol Z, Koturoglu G. Effects of *Saccharomyces boulardii* in children with acute diarrhoea. *Acta Paediatr* 2005;94:44-47.
- Kutteh WH, Koopman WJ, Conley ME, et al. Production of predominantly polymeric IgA by human peripheral blood lymphocytes stimulated in vitro with mitogens. *J Exp Med* 1980;152:1424-1429.
- Kwon J, Farrell R. Probiotics and inflammatory bowel disease. *BioDrugs* 2003;17(3):179-186. (Review)
- Lacour M, Zunder T, Huber R, et al. The pathogenetic significance of intestinal *Candida* colonization: a systematic review from an interdisciplinary and environmental medical point of view. *Int J Hyg Environ Health* 2002;205(4):257-268. (Review)
- Larsen CN, Nielsen S, Kæstel P, et al. Dose-response study of probiotic bacteria *Bifidobacterium animalis* subsp *lactis* BB-12 and *Lactobacillus paracasei* subsp *paracasei* CRL-341 in healthy young adults. *Eur J Clin Nutr* 2006;60:1284-1293.
- Leach JD, Gibson GR, Van Loo J. Human evolution, nutritional ecology and prebiotics in ancient diet. *Biosci Microflora* 2006;25(1):1-8.
- Leahy SC, Higgins DG, Fitzgerald GF, et al. Getting better with bifidobacteria. *J Appl Microbiol* 2005;98(6):1303-1315. (Review)
- Lee SJ, Ko WG, Kim JH, et al. Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. *Biochem Pharmacol* 2000;60:677-685.
- Lester BM, Boukydis CFZ, Garcia-Coll CT, et al. Colic for developmentalists. *Infant Mental Health J* 1990;11:321-333.
- Lewis SJ, Burmeister S. A double-blind placebo-controlled study of the effects of *Lactobacillus acidophilus* on plasma lipids. *Eur J Clin Nutr* 2005;59(6):776-780.
- Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. *Nature* 2006;444(7122):1022-1023.
- Lievín V, Peiffer I, Hudault S, et al. *Bifidobacterium* strains from resident infant human gastrointestinal microflora exert antimicrobial activity. *Gut* 2000;47:646-652.
- Linskens RK, Huijsdens XW, Savelkoul PH, et al. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. *Scand J Gastroenterol Suppl* 2001;(234):29-40. (Review)
- Lodinová-Zádníková R, Slavíková M, Tlaskalová-Hogenová H, et al. The antibody response in breast-fed and non-breast-fed infants after artificial colonization of the intestine with *Escherichia coli* O83. *Pediatr Res* 1991;29:396-399.
- Loizeau E. Can antibiotic-associated diarrhea be prevented? *Ann Gastroenterol Hepatol* 1993;29:15-18.
- Long SS, Swenson RM. Development of anaerobic fecal flora in healthy newborn infants. *J Pediatr* 1977;91:298-301.
- Lukaczer D, Lerman RH. Allergens, dysbiosis and immune dysregulation: case studies on inflammatory bowel disease. *Altern Ther Health Med* 2003;9(3):136,130-134.
- MacDonald TT. Development of mucosal immune function in man: potential for GI disease states. *Acta Paediatr Jpn* 1994;36:532-536.
- Macfarlane A. At last, maternity statistics for England. *BMJ* 1998;316:566-567.
- MacGregor G, Smith AJ, Thakker B, et al. Yoghurt biotherapy: contraindicated in immunosuppressed patients? *Postgrad Med J* 2002;78:366-367.
- Mahida YR, Rolfe VE. Host-bacterial interactions in inflammatory bowel disease. *Clin Sci (Lond)* 2004;107(4):331-341. (Review)
- Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. *J Allergy Clin Immunol* 1997;99:179-185.
- Malin M, Suomalainen H, Saxelin M, et al. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with *Lactobacillus GG*. *Ann Nutr Metab* 1996;40:137-145.
- Manzoni P, Mostert M, Leonessa ML, et al. Oral supplementation with *Lactobacillus casei* subspecies *rhamnosus* prevents enteric colonization by *Candida* species in preterm neonates: a randomized study. *Clin Infect Dis* 2006;42(12):1735-1742.
- Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of *Lactobacillus johnsonii* LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double-blind, placebo-controlled GETAID trial. *Gut* 2006;55(6):842-847.
- Marteau P, Seksik P, Jian R. Probiotics and health: new facts and ideas. *Curr Opin Biotechnol* 2002;13(5):486-489. (Review)
- Marteau P, Seksik P, Shanahan F. Manipulation of the bacterial flora in inflammatory bowel disease. *Best Pract Res Clin Gastroenterol* 2003;17(1):47-61. (Review)
- Marteau PR, de Vrese M, Cellier CJ, et al. Protection from gastrointestinal diseases with the use of probiotics. *Am J Clin Nutr* 2001;73(2 Suppl):430S-436S. (Review)
- Marteau PR. Probiotics in clinical conditions. *Clin Rev Allergy Immunol* 2002;22(3):255-273. (Review)
- Matricardi PM, Rosmini F, Ferrigno L, et al. Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. *BMJ* 1997;314:999-1003.

Citations and Reference Literature: Probiotics

- Matsumara K, Kitazawa H, Itoh T, et al. Interferon induction by murine peritoneal macrophage stimulated with *Lactobacillus gasseri*. *Anim Sci Technol (Jpn)* 1992;63:1157-1159.
- Mattila PS. Antibiotics in childhood acute otitis media. *Lancet* 2006;368:1397-1398.
- McBain AJ, Macfarlane GT. Investigations of bifidobacterial ecology and oligosaccharide metabolism in a three-stage compound continuous culture system. *Scand J Gastroenterol* 1997;32:32-40.
- McDonough FE, Hitchins AD, Wong NP, et al. Modification of sweet acidophilus milk to improve utilization by lactose-intolerant persons. *Am J Clin Nutr* 1987;45:570-574.
- McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of Beta-lactam-associated diarrhea by *Saccharomyces boulardii* compared with placebo. *Am J Gastroenterol* 1995;90:439-448.
- McGroarty JA. Probiotic use of lactobacilli in the human female urogenital tract. *FEMS Immunol Med Microbiol* 1993;6:251-264.
- Mellander L, Carlsson B, Hanson LÅ. Appearance of secretory IgM and IgA antibodies to *Escherichia coli* in saliva during early infancy and childhood. *J Pediatr* 1984;104:564-568.
- Mellander L, Carlsson B, Jalil F, et al. Secretory IgA antibody response against *Escherichia coli* antigens in infants in relation to exposure. *J Pediatr* 1985;107:430-433.
- Mel'nikova VM, Gracheva NM, Belikov GP, et al. The chemoprophylaxis and chemotherapy of opportunistic infections. *Antibiotiki i Khimioterapiia* 1993;38:44-48.
- Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. *J Clin Immunol* 1987;7:265-276.
- Meydani SN, Ha WK. Immunologic effects of yogurt. *Am J Clin Nutr* 2000;71(4):861-872.
- Meyer AL, Micksche M, Herbacek I, et al. Daily intake of probiotic as well as conventional yogurt has a stimulating effect on cellular immunity in young healthy women. *Ann Nutr Metab* 2006;50(3):282-289.
- Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of *Lactobacillus acidophilus* (johnsonii) La1 on *Helicobacter pylori* infection in humans. *Digestion* 1999;60(3):203-209.
- Mitsuyama K, Toyonaga A, Sata M. Intestinal microflora as a therapeutic target in inflammatory bowel disease. *J Gastroenterol* 2002;37(Suppl 14):73-77. (Review)
- Mitsuyama K. [Probiotics and prebiotics for the treatment of inflammatory bowel disease.] *Nippon Rinsho* 2005;63(5):850-858. [Japanese] (Review)
- Montalto M, Arancio F, Izzi D, et al. [Probiotics: history, definition, requirements and possible therapeutic applications] *Ann Ital Med Int* 2002;17(3):157-165. [Italian] (Review)
- Moreau MC, Ducluzeau R, Guy-Grand D, et al. Increase in the population of duodenal immunoglobulin A plasmacytes in axenic mice associated with different living or dead bacterial strains of intestinal origin. *Infect Immunol* 1978;21:532-539.
- Moro G, Arslanoglu S, Stahl B, et al. A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age. *Arch Dis Child* 2006;91(10):814-819.
- Murray MT, Pizzorno JE. Probiotics. In: Pizzorno JE, Murray MT, eds. *Textbook of natural medicine*. Vol 1. 2nd ed. Edinburgh: Churchill Livingstone; 1999:893-898.
- Myllyluoma E, Veijola L, Ahlroos T, et al. Probiotic supplementation improves tolerance to *Helicobacter pylori* eradication therapy: a placebo-controlled, double-blind randomized pilot study. *Aliment Pharmacol Ther* 2005;21:1263-1272.
- Neut C, Bezirtzoglou E, Romond C, et al. Bacterial colonization of the large intestine in newborns delivered by cesarean section. *Zentralbl Bakteriol Mikrobiol Hyg A* 1987;266:330-337.
- Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of *Lactobacillus plantarum* 299V in patients with irritable bowel syndrome. *Eur J Gastroenterol Hepatol* 2001;13:1143-1147.
- Nikawa H, Makihiro S, Fukushima H, et al. *Lactobacillus reuteri* in bovine milk fermented decreases the oral carriage of mutans streptococci. *Int J Food Microbiol* 2004;95:219-223.
- Ninonuevo MR, Park Y, Yin H, et al. A strategy for annotating the human milk glycome. *J Agric Food Chem* 2006;54(20):7471-7480.
- Niv E, Naftali T, Hallak R, et al. The efficacy of *Lactobacillus reuteri* ATCC 55730 in the treatment of patients with irritable bowel syndrome: a double blind, placebo-controlled, randomized study. *Clin Nutr* 2005;24(6):925-931.
- Nobaek S, Johansson M-L, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. *Am J Gastroenterol* 2000;95:1231-1238.
- Nyirjesy P, McIntosh MJ, Gattermeir DJ, et al. The effects of intravaginal clindamycin and metronidazole therapy on vaginal lactobacilli in patients with bacterial vaginosis. *Am J Obstet Gynecol* 2006;194(5):1277-1282.
- O'Mahony L, McCarthy J, Kelly P, et al. *Lactobacillus* and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. *Gastroenterology* 2005;128(3):541-550.

Citations and Reference Literature: Probiotics

- Oberhelman RA, Gilman RH, Sheen P, et al. A placebo-controlled trial of *Lactobacillus* GG to prevent diarrhea in undernourished Peruvian children. *J Pediatr* 1999;134:15-20.
- Oksanen PJ, Salminen S, Saxelin M, et al. Prevention of traveller's diarrhoea by *Lactobacillus* GG. *Ann Med* 1990;22:53-56.
- Olah A, Belagyi T, Issekutz A, et al. Randomized clinical trial of specific *Lactobacillus* and fibre supplement to early enteral nutrition in patients with acute pancreatitis. *Br J Surg* 2002;89:1103-1107.
- Op den Camp HJM, Oosterhof A, Veerkamp JH. Interaction of bifidobacterial lipoteichoic acid with human intestinal epithelial cells. *Infect Immun* 1984;47:332-334.
- Osman N, Adawi D, Ahrne S, et al. Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of *Lactobacillus* and *Bifidobacterium*. *Dig Dis Sci* 2004;49(2):320-327.
- O'Sullivan MA, et al. Bacterial supplementation in the irritable bowel syndrome: a randomized double-blind placebo-controlled crossover study. *Digest Liver Dis* 2000;32:294-301.
- Pantoflickova D, Cortesey-Theulaz I, Dorta G, et al. Favourable effect of regular intake of fermented milk containing *Lactobacillus johnsonii* on *Helicobacter pylori* associated gastritis. *Aliment Pharmacol Ther* 2003;18(8):805-814.
- Pavan S, Desreumaux P, Mercenier A. Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria. *Clin Diagn Lab Immunol* 2003;10(4):696-701.
- Pedone CA, Bernabeu AO, Postaire ER, et al. The effect of supplementation with milk fermented by *Lactobacillus casei* (strain DN-114 001) on acute diarrhoea in children attending day care centres. *Int J Clin Pract* 1999;53:179-184.
- Pelto L, Isolauri E, Lilius EM, et al. Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects. *Clin Exp Allergy* 1998;28:1474-1479.
- Perapoch J, Planes AM, Querol A, et al. Fungemia with *Saccharomyces cerevisiae* in two newborns, only one of whom had been treated with Ultra-Levura. *Eur J Clin Microbiol Infect Dis* 2000;19:468-470.
- Perdigon G, Alvarez S, Rachid M, et al. Immune system stimulation by probiotics. *J Dairy Sci* 1995;78:1597-1606.
- Perdigon G, Nader De Macios ME, et al. Effect of perorally administered *Lactobacilli* on macrophage activation in mice. *Infect Immun* 1986;53:404-410.
- Persky SE, Brandt LJ. Treatment of recurrent *Clostridium difficile*-associated diarrhea by administration of donated stool directly through a colonoscope. *Am J Gastroenterol* 2000;95(11):3283-3285.
- Pirotta M, Gunn J, Chondros P, et al. Effect of *Lactobacillus* in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial. *BMJ* 2004;329:548.
- Plein K, Hotz J. Therapeutic effects of *Saccharomyces boulardii* on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea-a pilot study. *Z Gastroenterol* 1993;31:129-134.
- Plummer S, Weaver MA, Harris JC, et al. *Clostridium difficile* pilot study: effects of probiotic supplementation on the incidence of *C. difficile* diarrhoea. *Int Microbiol* 2004;7(1):59-62.
- Plummer SF, Garaiova I, Sarvotham T, et al. Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy. *Int J Antimicrob Agents* 2005;26(1):69-74.
- Pradhan A, Majumdar MK. Metabolism of some drugs by intestinal *Lactobacilli* and their toxicological considerations. *Acta Pharmacol Toxicol (Copenh)* 1986;58(1):11-15.
- Pruden A, Pei R, Storteboom H, et al. Antibiotic resistance genes as emerging contaminants: studies in Northern Colorado [ASAP article]. *Environ Sci Technol* 2006; DOI:10.1021/es060413l.
- Pulverer G, Ko HL, Roszkowski W, et al. Digestive tract microflora liberates low molecular weight peptides with immunotrigging activity. *Int J Med Microbiol* 1990;272:318-327.
- Rani B, Khetarpaul N. Probiotic fermented food mixtures: possible applications in clinical anti-diarrhea usage. *Nutr Health* 1998;12(2): 97-105.
- Rasic JL. The role of dairy foods containing bifido and acidophilus bacteria in nutrition and health. *N Eur Dairy J* 1983;4:80-88.
- Rath HC. The role of endogenous bacterial flora: bystander or the necessary prerequisite? *Eur J Gastroenterol Hepatol* 2003;15(6): 615-620. (Review)
- Reddy BS, Rivenson A. Inhibitory effect of *Bifidobacterium longum* on colon, mammary, and liver carcinogenesis induced by 2-amino-3-methylimidazo [4,5-f] quinoline, a food mutagen. *Cancer Res* 1993;53:3914-3918.
- Reid G, Bruce AW, McGroarty JA, et al. Is there a role for *Lactobacilli* in prevention of urogenital and intestinal infections? *Clin Microbiol Rev* 1990;3:335-344.
- Reid G, Charbonneau D, Erb J, et al. Oral use of *Lactobacillus rhamnosus* GR-1 and *L. fermentum* RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. *FEMS Immunol Med Microbiol* 2003;35:131-134.
- Reid G, Millsap K, Bruce AW. Implantation of *Lactobacillus casei* var *rhamnosus* into vagina. *Lancet* 1994;344:1229.

Citations and Reference Literature: Probiotics

- Reid G. Probiotic agents to protect the urogenital tract against infection. *Am J Clin Nutr* 2001;73(2 Suppl):437S-443S. (Review)
- Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic *Escherichia coli* versus mesalazine for the treatment of ulcerative colitis: a randomized trial. *Lancet* 1999;354:635-639.
- Reuter G. The *Lactobacillus* and *Bifidobacterium* microflora of the human intestine: composition and succession. *Curr Issues Intest Microbiol* 2001;2(2):43-53. (Review)
- Richelsen B, Kristensen K, Pedersen SB. Long-term (6 months) effect of a new fermented milk product on the level of plasma lipoproteins-a placebo-controlled and double blind study. *Eur J Clin Nutr* 1996;50:811-815.
- Rioux KP, Madsen KL, Fedorak RN. The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. *Gastroenterol Clin North A* 2005;34(3):465-482,ix. (Review)
- Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. *J Nutr* 2000;130(2S Suppl):396S-402S.
- Rook GAW, Stanford JA. Give us this day our daily germs. *Immunol Today* 1998;19:113-116.
- Rosenfeldt V, Benfeldt E, Nielsen SD, et al. Effect of probiotic *Lactobacillus* strains in children with atopic dermatitis. *J Allergy Clin Immunol* 2003;111:389-395.
- Rosenfeldt V, Michaelsen KF, Jakobsen M, et al. Effect of probiotic *Lactobacillus* strains in young children hospitalized with acute diarrhea. *Pediatr Infect Dis J* 2002;21:411-416.
- Rothkötter HJ, Pabst R. Lymphocyte subsets in jejunal and ileal Peyer's patches of normal and gnotobiotic minipigs. *Immunology* 1989;67:103-108.
- Rousseaux C, Thuru X, Gelot A, et al. *Lactobacillus acidophilus* modulates intestinal pain and induces opioid and cannabinoid receptors. *Nature Med* 2007;13(1):35-37. Epub 2006; doi:10.1038/nm1521.
- Rovers MM, et al. Antibiotics for acute otitis media: a meta-analysis with individual patient data. *Lancet* 2006;368:1429-1434.
- Rowland IR, Grasso P. Degradation of N-nitrosamines by intestinal bacteria. *Appl Microbiol* 1975;29:7-12.
- Saavedra JM, Bauman NA, Oung I, et al. Feeding of *Bifidobacterium bifidum* and *Streptococcus thermophilus* to infants in hospital for prevention of diarrhoea and shedding of rotavirus. *Lancet* 1994;344:1046-1049.
- Saavedra JM, Bauman NA, Oung I, et al. Feeding of *Bifidobacterium bifidum* and *Streptococcus thermophilus* to infants in hospital for prevention of diarrhoea and shedding of rotavirus. *Lancet* 1994;344:1046-1049.
- Saggioro A. Probiotics in the treatment of irritable bowel syndrome. *J Clin Gastroenterol* 2004;38(6 Suppl):S104-106. Erratum in *J Clin Gastroenterol* 2005;39(3):261.
- Sakamoto I, Igarashi M, Kimura K, et al. Suppressive effect of *Lactobacillus gasseri* OLL 2716 (LG21) on *Helicobacter pylori* infection in humans. *J Antimicrob Chemother* 2001;47:709-710.
- Salazar-Lindo E, Miranda-Langschwager P, Campos-Sanchez M, et al. *Lactobacillus casei* strain GG in the treatment of infants with acute watery diarrhea: a randomized, double-blind, placebo controlled clinical trial. *BMC Pediatr* 2004 2;4:18.
- Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. *Gastroenterology* 2004;126(6):1620-1633. (Review)
- Savilahti E. Immunoglobulin-containing cells in the intestinal mucosa and immunoglobulins in the intestinal juice in children. *Clin Exp Immunol* 1972;11:415-425.
- Scarpignato C, Rampal P. Prevention and treatment of traveler's diarrhea: a clinical pharmacological approach. *Chemotherapy* 1995;41(Suppl 1):48-81. (Review)
- Schiffrin EJ, Brassart D, Servin AL, et al. Immune modulation of blood leukocytes in humans by lactic acid bacteria: criteria for strain selection. *Am J Clin Nutr* 1997;66(2):515S-520S.
- Schultz M, Munro K, Tannock GW, et al. Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats. *Clin Diagn Lab Immunol* 2004;11(3):581-587.
- Schultz M, Sartor RB. Probiotics and inflammatory bowel diseases. *Am J Gastroenterol* 2000;95(1 Suppl):S19-S21. (Review)
- Sedgwick JD, Holt PG. A solid-phase immunoenzymatic technique for the enumeration of specific antibodysecreting cells. *J Immunol Methods* 1983;57:301-9.
- Sekine K, Watanabe-Sekine E, Ohta J, et al. Induction and activation of tumoricidal cells in vitro and in vivo by the bacterial cell wall of *Bifidobacterium infantis*. *Bifidobacteria Microflora* 1994;13:65-77.
- Sen S, Mullan MM, Parker TJ, et al. Effect of *Lactobacillus plantarum* 299v on colonic fermentation and symptoms of irritable bowel syndrome. *Dig Dis Sci* 2002;47:2615-2620.
- Seppo L, Jauhiainen T, Poussa T, et al. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. *Am J Clin Nutr* 2003;77:326-330.
- Shaheen SO, Aaby P, Hall AJ, et al. Measles and atopy in Guinea-Bissau. *Lancet* 1996;347:1792-1796.

Citations and Reference Literature: Probiotics

- Shalev E, Battino S, Weiner E, et al. Ingestion of yogurt containing *Lactobacillus acidophilus* compared with pasteurized yogurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis. *Arch Fam Med* 1996;5(10):593-596.
- Shanahan F. Host-flora interactions in inflammatory bowel disease. *Inflamm Bowel Dis* 2004;10(Suppl 1):S16-S24. (Review)
- Shanahan F. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I: pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. *Am J Physiol Gastrointest Liver Physiol* 2005;288(3):G417-G421. (Review)
- Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? *Inflamm Bowel Dis* 2000;6(2):107-115.
- Shanahan F. Probiotics in inflammatory bowel disease: therapeutic rationale and role. *Adv Drug Deliv Rev* 2004;56(6):809-818. (Review)
- Sheih YH. Systemic immunity-enhancing effects in health subjects following dietary consumption of the lactic acid bacterium *Lactobacillus rhamnosus* HN001. *J Am Coll Nutr* 2001;20(2):149-156.
- Sheu B-S, Cheng H-C, Kao A-W, et al. Pretreatment with *Lactobacillus*- and *Bifidobacterium*-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual *Helicobacter pylori* infection after failed triple therapy. *Am J Clin Nutr* 2006 83:864-869.
- Shirakawa T, Enomoto T, Shimazu S, et al. The inverse association between tuberculin responses and atopic disorder. *Science* 1997;275:77-79.
- Shornikova AV, Casas IA, Isolauri E, et al. *Lactobacillus reuteri* as a therapeutic agent in acute diarrhea in young children. *J Pediatr Gastroenterol Nutr* 1997;24:399-404.
- Shornikova AV, Casas IA, Mykkanen H, et al. Bacteriotherapy with *Lactobacillus reuteri* in rotavirus gastroenteritis. *Pediatr Infect Dis J* 1997;16:1103-1107.
- Siitonen S, Vapaatalo H, Salminen S, et al. Effect of *Lactobacillus GG* yoghurt in prevention of antibiotic associated diarrhoea. *Ann Med* 1990;22:57-59.
- Silva M, Jacobus NV, Deneke C, et al. Antimicrobial substance from a human *Lactobacillus* strain. *Antimicrob Agents Chemother* 1987;31:1231-1233.
- Simakachorn N, Pichaiapat V, Rithipornpaisarn P, et al. Clinical evaluation of the addition of lyophilized, heat-killed *Lactobacillus acidophilus* LB to oral rehydration therapy in the treatment of acute diarrhea in children. *J Pediatr Gastroenterol Nutr* 2000;30:68-72.
- Simon GL, Gorbach SL. Intestinal flora in health and disease. *Gastroenterology* 1984;86:174-193.
- Smirnov VV, Reznik SR, V'iunitskaia VA, et al. The current concepts of the mechanisms of the therapeutic-prophylactic action of probiotics from bacteria in the genus *Bacillus*. *Mikrobiologichnyi Zhurnal* 1993;55:92-112.
- Solis Pereyra B, Lemmonier D. Induction of human cytokines to bacteria used in dairy foods. *Nutr Res* 1993;13:1127-1140.
- Sozinov AS, Abdulkhakov SR, Kiyasov AP, et al. Alteration of the liver in rats with experimental dysbiosis. *Bull Exp Biol Med* 2003;136(1):19-21.
- Sozinov AS, Pozdeev OK, Lapshina GN, et al. [Intestinal microflora in rats under the conditions of a chronic toxic lesion of the liver.] *Zh Mikrobiol Epidemiol Immunobiol* 2002;(3):60-63. [Russian]
- Spiro DM, Tay K-Y, Arnold DH, et al. Wait-and-see prescription for the treatment of acute otitis media: a randomized controlled trial. *JAMA* 2006;296:1235-1241.
- Standiford TK, Arenberg DA, Danforth JM, et al. Lipoteichoic acid induces secretion of interleukin-8 from human blood monocytes: a cellular and molecular analysis. *Infect Immun* 1994;62:119-125.
- Stenina MA, Voevodin DA, Stakhanov VD, et al. Tissue hypoxia and intestinal dysbiosis in children with tuberculosis. *Bull Exp Biol Med* 2003;135(2):178-180.
- Stone-Dorshow T, Levitt MD. Gaseous response to ingestion of a poorly absorbed fructooligosaccharide sweetener. *Am J Clin Nutr* 1987;46:61-65.
- Sudo N, Sawamura S, Tanaka K, et al. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. *J Immunol* 1997;159:1739-1745.
- Sullivan A, Johansson A, Svenungsson B, et al. Effect of *Lactobacillus F19* on the emergence of antibiotic-resistant microorganisms in the intestinal microflora. *J Antimicrob Chemother* 2004;54(4):791-797.
- Surawicz CM, Elmer G, Speelman P, et al. Prevention of antibiotic-associated diarrhea by *Saccharomyces boulardii*: a prospective study. *Gastroenterology* 1989;9:981-988.
- Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by *Saccharomyces boulardii*: a prospective study. *Gastroenterology* 1989;96:981-988.
- Surawicz CM, McFarland LV, Elmer G, et al. Treatment of recurrent *Clostridium difficile* colitis with vancomycin and *Saccharomyces boulardii*. *Am J Gastroenterol* 1989;84:1285-1287.
- Sussman J, Baron E, Goldberg S, et al. Clinical manifestations of *Lactobacillus* endocarditis: report of a case and review of the literature. *Rev Infect Dis* 1986;8:771-776.

Citations and Reference Literature: Probiotics

- Szajewska H, Kotowska M, Mrukowicz JZ, et al. Efficacy of *Lactobacillus* GG in prevention of nosocomial diarrhea in infants. *J Pediatr* 2001;138:361-365.
- Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. *J Pediatr Gastroenterol Nutr* 2001;33(4 Suppl):S17-S25.
- Szajewska H, Mrukowicz JZ. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. *J Pediatr Gastroenterol Nutr* 2001;33(4 Suppl):S17-S25.
- Talayero JMP, Lizán-García M, PuimeÁO, et al. Full breastfeeding and hospitalization as a result of infections in the first year of life. *Pediatrics* 2006;118:e92-e99.
- Tamboli CP, Caucheteux C, Cortot A, et al. Probiotics in inflammatory bowel disease: a critical. *Best Pract Res Clin Gastroenterol* 2003;17(5):805-820. (Review)
- Tamboli CP, Caucheteux C, Cortot A, et al. Probiotics in inflammatory bowel disease: a critical review. *Best Pract Res Clin Gastroenterol* 2003;17(5):805-820. (Review)
- Tamboli CP, Neut C, Desreumaux P, et al. Dysbiosis as a prerequisite for IBD. *Gut* 2004;53(7):1057.
- Tamboli CP, Neut C, Desreumaux P, et al. Dysbiosis in inflammatory bowel disease. *Gut* 2004;53(1):1-4.
- Tankanow RM, Ross MB, Ertel IJ, et al. A double-blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhea. *DICP* 1990;24:382-384.
- Tejada-Simon MV, Lee JH, Ustunol Z, et al. Ingestion of yogurt containing *Lactobacillus acidophilus* and *Bifidobacterium* to potentiate immunoglobulin A responses to cholera toxin in mice. *J Dairy Sci* 1999;82(4):649-660.
- Teramoto F, Rokutan K, Kawakami Y, et al. Effect of 4G-beta-D-galactosylsucrose (lactosucrose) on fecal microflora in patients with chronic inflammatory bowel disease. *J Gastroenterol* 1996;31(1):33-39.
- Thibault H, Aubert-Jacquín C, Goulet O. Effects of long-term consumption of a fermented infant formula (with *Bifidobacterium breve* c50 and *Streptococcus thermophilus* 065) on acute diarrhea in healthy infants. *J Pediatr Gastroenterol Nutr* 2004;39:147-152.
- Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of *Lactobacillus* GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. *Mayo Clin Proc* 2001;76:883-889.
- Thompson-Chagoyan OC, Maldonado J, Gil A. Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. *Clin Nutr* 2005;24(3):339-352. (Review)
- Tojo M, Oikawa T, Morikawa Y, et al. The effects of *Bifidobacterium breve* administration on campylobacter enteritis. *Acta Pediatr Jpn* 1987;29:160-167.
- Tubelius P, Stan V, Zachrisson A. Increasing work-place healthiness with the probiotic *Lactobacillus reuteri*: a randomised, double-blind placebo-controlled study. *Environ Health* 2005;4:25.
- Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 2006;444(7122):1027-1031.
- Unger C, Haring B, Kruse A, et al. Double-blind randomised placebo-controlled phase III study of an *E. coli* extract plus 5-fluorouracil versus 5-fluorouracil in patients with advanced colorectal cancer. *Arzneimittelforschung* 2001;51:332-338.
- Urbancsek H, Kazar T, Mezes I, et al. Results of a double-blind, randomized study to evaluate the efficacy and safety of *Antibiofilus* in patients with radiation-induced diarrhoea. *Eur J Gastroenterol Hepatol* 2001;13:391-396.
- Usviatsov BIa, Parshuta LI, Dolgov VA. [Microbial biocenosis in the mucous membranes of the nose and the middle ear in patients with purulent otitis.] *Zh Mikrobiol Epidemiol Immunobiol* 2000;(4 Suppl):85-88. [Russian]
- Van der Heijden PJ, Bianchi AT, Stok W, et al. Background (spontaneous) immunoglobulin production in the murine small intestine as a function of age. *Immunology* 1988;65:243-248.
- Van der Heijden PJ, Stok W, Bianchi AT. Contribution of immunoglobulin-secreting cells in the murine small intestine to the total 'background' immunoglobulin production. *Immunology* 1987;62:551-555.
- Van Niel CW, Feudtner C, Garrison M, et al. *Lactobacillus* therapy for acute infections diarrhea in children: a meta-analysis. *Pediatrics* 2002;109(4):678-684.
- Vanderhoof JA, Whitney DB, Antonson DL, et al. *Lactobacillus* GG in the prevention of antibiotic-associated diarrhea in children. *J Pediatr* 1999;135(5):564-568.
- Vanderhoof JA. Probiotics and intestinal inflammatory disorders in infants and children. *J Pediatr Gastroenterol Nutr* 2000;30(Suppl 2):S34-S38. (Review)
- Veldman A. Probiotics. *Tijdschrift voor Diergeneeskunde* 1992;117:345-348.
- Viljanen M, Savilahti E, Haahela T et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. *Allergy* 2005;60:494-500.
- Wakabayashi C, Murakami K, Hasegawa H, et al. An intestinal bacterial metabolite of ginseng protopanaxadiol saponins has the ability to induce apoptosis in tumor cells. *Biochem Biophys Res Commun* 1998;246(3):725-730.

Citations and Reference Literature: Probiotics

- Waligora-Dupriet AJ, Campeotto F, Nicolis I, et al. Effect of oligofructose supplementation on gut microflora and well-being in young children attending a day care centre. *Int J Food Microbiol* 2007;113(1):108-113.
- Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. *Pediatrics* 2005;115(1):5-9.
- Wendakoon CN, Thomson AB, Ozimek L. Lack of therapeutic effect of a specially designed yogurt for the eradication of *Helicobacter pylori* infection. *Digestion* 2002;65:16-20.
- Weston S, Halbert A, Richmond P, et al. Effects of probiotics on atopic dermatitis: a randomised controlled trial. *Arch Dis Child* 2005;90(9):892-897.
- Williams CH, Witherly SA, Buddington, RK. Influence of dietary neosugar on selected bacterial groups of the human faecal microbiota. *Microb Ecol Health Dis* 1994;7:91-97.
- Winkler P, de Vrese M, Laue Ch, et al. Effect of a dietary supplement containing probiotic bacteria plus vitamins and minerals on common cold infections and cellular immune parameters. *Int J Clin Pharmacol Ther* 2005;43(7):318-326.
- Wullt M, Hagslatt ML, Odenholt I. *Lactobacillus plantarum* 299v for the treatment of recurrent *Clostridium difficile*-associated diarrhoea: a double-blind, placebo-controlled trial. *Scand J Infect Dis* 2003;35(6-7):365-367.
- Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing *Lactobacillus acidophilus* and *Lactobacillus casei* in high fructose fed rats. *Nutrition* 2007;23(1):62-68.
- Yamazaki S, Kamimura H, Momose H, et al. Protective effect of bifidobacterium monoassociation against lethal activity of *E coli*. *Bifidobacteria Microflora* 1982;1:55-60.
- Yasui H, Nagaoka N, Mike A, et al. Detection of bifidobacterium strains that induce large quantities of IgA. *Microb Ecol Health Dis* 1992;5:155-162.
- Yasui H, Ohwaki M. Enhancement of immune response in Peyer's patch cells cultured with *Bifidobacterium breve*. *J Dairy Sci* 1991;74:1187-1195.
- Yoshioka H, Iseki K, Fujita K. Development and differences of intestinal flora in the neonatal period in breast-fed and bottle-fed infants. *Pediatrics* 1983;72:317-321.
- Zang XB, Ohta Y, Hosono A. Antimutagenicity and binding of lactic bacteria from a Chinese cheese to mutagenic pyrolyzates. *J Dairy Sci* 1990;73:2702-2710.
- Zareie M, Johnson-Henry KC, Jury J, et al. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. *Gut* 2006;000:1-8.